SUVEN · NSE Healthcare Large Cap

Suven Life Sciences Limited

SUVEN  ·  National Stock Exchange of India

SUVEN is currently trading at ₹261, 21.7% below its 50-day moving average. The Kasauti methodology audit finds 5 of 8 structural parameters confirmed, placing this instrument in the Does Not Pass Yet category.

Data Execution Timestamp: 23 October 2026 · NSE Closing Bell
Overall Verdict
अभी नहीं मित्र
Does Not Pass Yet
Minervini SEPA 5 / 8
Weinstein Stage Stage 1 — Base
Base Advance Top Decline
52-Week Price History — Weekly
₹261 Snapshot · NSE Closing Bell · 23 Oct 2026
₹124 ₹192 ₹260 ₹329 ₹397 Oct '25 Jan '26 Apr '26 Jul '26 Oct '26 52W H ₹390
Weekly close 50 DMA 200 DMA 52W high

Minervini SEPA — 8 Parameter Audit

Parameter Result Data
Price above 150 & 200 DMA
Minervini SEPA · Criterion 1
FAIL Price ₹261 · 150 DMA ₹278 · 200 DMA ₹246
150 DMA above 200 DMA
Minervini SEPA · Criterion 2
PASS 150 DMA ₹278 vs 200 DMA ₹246 (+13.1%)
200 DMA trending up ≥ 1 month
Minervini SEPA · Criterion 3
PASS 200 DMA slope: +4.87% over 4 weeks
50 DMA above 150 & 200 DMA
Minervini SEPA · Criterion 4
PASS 50 DMA ₹334 · 150 DMA ₹278 · 200 DMA ₹246
Price above 50 DMA
Minervini SEPA · Criterion 5
FAIL Price ₹261 · 50 DMA ₹334 (-21.7%)
Price within 25% of 52-week high
Minervini SEPA · Criterion 6
FAIL ₹261 vs 52W high ₹403 (-35.2%)
Price ≥ 30% above 52-week low
Minervini SEPA · Criterion 7
PASS ₹261 vs 52W low ₹124 (+110.6%)
RS Rating ≥ 70
Minervini SEPA · Criterion 8
PASS RS Rating: 87 (threshold: ≥70)

Weinstein Stage Analysis

Stage 1
Base
Stage 2
Advance
Stage 3
Top
Stage 4
Decline

SUVEN.NS is in Weinstein Stage 1 — the basing phase. The stock is consolidating after a prior decline, trading sideways around or below its 200-day moving average. Position traders applying strict methodology do not participate during Stage 1.

Relative Strength Rating

87 Stronger than 87% of the NSE universe
↓ Declining over 13 weeks

Structural Analysis

Suven Life Sciences Limited is currently trading 21.7% below its 50-day moving average, with Weinstein Stage 1 confirmed by the moving average hierarchy.

The Minervini SEPA audit finds 5 of 8 parameters confirmed. The parameter(s) not confirmed: Price above 150 & 200 DMA, Price above 50 DMA, Within 25% of 52W high.

Sanjaya's Reading

The Witness Speaks

Mitra, main dekh raha hoon Suven Life Sciences Limited ko — 5 criteria poore hain aath mein se.

Weinstein Stage 1 mein hai yeh instrument. अभी नहीं मित्र.

This is a static snapshot

This audit was generated from NSE closing data on 23 October 2026. Run a live audit with real-time data, animated criteria reveals, and Sanjaya's full narration.

Run a Live Audit — Free →

Free tier includes Nifty 50 stocks · Pro unlocks full NSE universe

Frequently Asked Questions

Does SUVEN pass the Minervini SEPA criteria?▾

SUVEN (Suven Life Sciences Limited) currently meets 5 of 8 Minervini SEPA parameters. SUVEN currently meets 5 of 8 Minervini SEPA parameters. The parameter(s) not confirmed: Price above 150 & 200 DMA, Price above 50 DMA, Within 25% of 52W high.

What is the Weinstein Stage Analysis for SUVEN?▾

SUVEN is currently in Weinstein Stage 1. SUVEN.NS is in Weinstein Stage 1 — the basing phase. The stock is consolidating after a prior decline, trading sideways around or below its 200-day moving average. Position traders applying strict methodology do not participate during Stage 1.

Is SUVEN structurally aligned for position trading?▾

The Kasauti verdict for SUVEN is अभी नहीं मित्र (Does Not Pass Yet). The Kasauti verdict for SUVEN.NS is अभी नहीं मित्र — Does Not Pass Yet. With 5 of 8 criteria met, the primary area to monitor is: Price above 150 & 200 DMA, Price above 50 DMA, Within 25% of 52W high. This is a structural methodology assessment only — not a recommendation to deploy or exit capital. This is a structural methodology assessment only — not a recommendation to deploy or exit capital.

Methodology Assessment Disclaimer: This page presents a systematic structural audit of SUVEN against methodology parameters derived from the published works of Mark Minervini and Stan Weinstein. All data is sourced from NSE end-of-day prices. This content is for educational and analytical purposes only. Kasauti™ does not provide investment advice, stock recommendations, or capital deployment directives. Always conduct independent research and consult a SEBI-registered investment adviser before making any financial decisions.